Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · IEX Real-Time Price · USD
5.85
-0.07 (-1.18%)
Apr 19, 2024, 4:00 PM EDT - Market closed
Company Description
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases.
It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Monte Rosa Therapeutics, Inc.
| Country | United States |
| Founded | 2019 |
| IPO Date | Jun 24, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 133 |
| CEO | Dr. Markus Warmuth M.D. |
Contact Details
Address: 321 Harrison Avenue, Suite 900 Boston, Massachusetts 02118 United States | |
| Phone | 617-949-2643 |
| Website | monterosatx.com |
Stock Details
| Ticker Symbol | GLUE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001826457 |
| CUSIP Number | 61225M102 |
| ISIN Number | US61225M1027 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Markus Warmuth M.D. | President, Chief Executive Officer and Director |
| Dr. Owen B. Wallace Ph.D. | Chief Scientific Officer |
| Dr. Filip Janku M.D., Ph.D. | Chief Medical Officer |
| Jennifer Champoux | Chief People and Operations Officer |
| Dr. Sharon Townson Ph.D. | Chief Technology Officer |
| Dr. John C. Castle Ph.D. | Chief Data and Information Officer |
| Andrew Funderburk | Senior Vice President and Head of IR and Strategic Finance |
| Philip Nickson J.D., Ph.D. | General Counsel |
| Magnus Walter DPHIL | Senior Vice President of Drug Discovery |
| Edmund Dunn | Vice President and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2024 | 144 | Filing |
| Apr 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 14, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 14, 2024 | 10-K | Annual Report |
| Mar 14, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |